

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 7, 2016

**AETHLON MEDICAL, INC.**  
(Exact name of registrant as specified in its charter)

Nevada  
(State or other jurisdiction  
of incorporation)

001-37487  
(Commission File Number)

13-3632859  
(IRS Employer  
Identification Number)

9635 Granite Ridge Drive, Suite 100  
San Diego, California  
(Address of principal executive offices)

92123  
(Zip Code)

Registrant's telephone number, including area code: (858) 459-7800

Not applicable  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## FORWARD-LOOKING STATEMENTS

This Form 8-K and other reports filed by the registrant from time to time with the Securities and Exchange Commission (collectively, the "Filings") contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the registrant's management as well as estimates and assumptions made by the registrant's management. When used in the Filings the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan" or the negative of these terms and similar expressions as they relate to the registrant or the registrant's management identify forward-looking statements. Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant's industry, the registrant's operations and results of operations and any businesses that may be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although the registrant believes that the expectations reflected in the forward-looking statements are reasonable, the registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

### ITEM 7.01 REGULATION FD DISCLOSURE.

Today, June 7, 2016, Mr. James Joyce, Chief Executive Officer of Aethlon Medical, Inc. (the "Company"), presented at the BIO International Convention. A link to the presentation may be accessed on the Company's website under the investor relations section of the website. The website address is [www.aethlonmedical.com](http://www.aethlonmedical.com). No portion of the website shall be deemed to be incorporated into this Current Report on Form 8-K.

### ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. (d) EXHIBITS

EXHIBIT NO.	DESCRIPTION
99.1	Presentation materials – BIO International Convention – June 7, 2016

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.

By: /s/ James B. Frakes  
James B. Frakes  
Chief Financial Officer

Dated: June 7, 2016

## EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Presentation materials – BIO International Convention – June 7, 2016

# Aethlon Medical, Inc.

Nasdaq: AEMD

BIO International Convention  
San Francisco  
June 7, 2016

Jim Joyce  
Chairman, CEO



# FORWARD LOOKING STATEMENTS

*The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon ADAPT™ and ELLSA™ platform technologies, the Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at [www.sec.gov](http://www.sec.gov) or on our website: [www.AethlonMedical.com](http://www.AethlonMedical.com)*



# IMMUNOTHERAPEUTIC TECHNOLOGIES TO COMBAT INFECTIOUS DISEASE & CANCER



SAVE LIVES





# Summary

- Clinical-stage Company
- Lead therapeutic – The Aethlon Hemopurifier®
  - Broad-spectrum countermeasure against emerging pandemic threats
  - Discovered to capture cancer-promoting exosomes
    - Significant unmet need in cancer care
- Exosome Sciences, Inc. (*diagnostic subsidiary*)
  - ELLSA™ exosome isolation platform (*virus & cancer*)
  - Discovered a candidate biomarker to diagnose CTE



# The Aethlon Hemopurifier®



Broad-spectrum elimination of circulating viruses, viral particles and bacterial toxins





DEPLOYED WITHIN THE GLOBAL INFRASTRUCTURE OF DIALYSIS & CRRT MACHINES



# The Hemopurifier® Mechanism of Action

- Rapid separation of disease targets from the circulatory blood path
- Capture of disease targets through adherence to surface structure that provides immune-evasion
  - Lectin-affinity attachment to high-mannose signature that cloaks pathogen targets from immune surveillance



*The Hemopurifier® establishes a therapeutic strategy to address the hundreds of viruses that are not treatable with antiviral drug agents.*



# The Aethlon Hemopurifier®




FDA approved IDE study currently being conducted





## Previous Human Treatment Experiences





BROAD-SPECTRUM HUMAN TREATMENT EXPERIENCES





# The Treatment of Ebola Virus

## Frankfurt University Hospital



Special approval from The Federal Institute for Drugs and Medical Devices (BfArM)





Hemopurifier® therapy  
administration to a  
comatose Ebola patient  
with multiple-organ failure





Dr. Stefan Büttner  
Holding Hemopurifier®  
After Ebola Treatment



# Ebola Treatment Data

Presented By Dr. Helmut Geiger

American Society of Nephrology Annual Meeting

- 6.5 hour Hemopurifier® therapy administration
- Pre-treatment viral load: 400,000 copies/ml
- Post-treatment viral load: 1,000 copies/ml
- Patient recovered and returned home



## Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease – First Experience with Lectin Affinity Plasmapheresis

- Stefan Büttner<sup>a</sup> Benjamin Koch<sup>a</sup> Olga Dolnik<sup>b</sup> Markus Eickmann<sup>b</sup> Tilo Freiwald<sup>a</sup> Sarah Rudolf<sup>a</sup> Jürgen Engel<sup>a</sup> Stephan Becker<sup>b</sup> Claudio Ronco<sup>c</sup> Helmut Geiger<sup>a</sup>
- <sup>a</sup> Medical Clinic III, Department of Nephrology, University Hospital Frankfurt, Frankfurt am Main, and <sup>b</sup> Institute of Virology, Philipps University Marburg, Marburg, Germany; <sup>c</sup> Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy
- Published: Journal of Blood Purification







“Top 25 Best Inventions”

“11 Most Remarkable Advances in Healthcare”



# Pre-clinical Validations

(Reported to date)



## *In Vitro* Hemopurifier® Validations

- Viruses
  - Hepatitis C, HIV, Ebola, H1N1 Swine Flu, H5N1 Bird Flu, 1918 Spanish Flu (reconstructed), Monkey Pox, West Nile Virus, Chikungunya and Dengue
- Viral Toxins
  - Ebola glycoprotein (gp), HIV gp120, HIV NEF-exosomes
- Bacterial Toxins
  - Lipopolysaccharide (LPS) and Lipoteichoic acid (LTA)
- **Tumor-derived Exosomes**







## CANCER

Initiated tumor-derived  
exosome research in 2006

*Considered cellular debris with  
no biological function*




2016

*Tumor-derived exosomes are significant  
therapeutic and diagnostic targets*



## Tumor-Derived Exosomes



# Tumor-Derived Exosomes

## A Significant Unmet Medical Need in Cancer

- The seeds of cancer metastasis
  - Metastasis contributes to 90% of cancer deaths
  - The mystery of the Soil & Seed Theory of 1889
- Tumor-derived exosomes promote:
  - Tumorigenesis
  - Cancer progression
  - Angiogenesis
  - Immune-evasion
  - Resistance to radiation and chemotherapeutic drugs




*The Hemopurifier® provides an adjunct strategy to optimize emerging immuno-oncology drugs or improve the benefit of chemotherapeutic regimens*









ELLSA™ (Enzyme-linked lectin-specific assay)  
Proprietary exosome isolation platform




# ELLSA™

- Isolates disease-origin exosomes from bodily fluids
  - ELLSA step + specific antibody step to diagnose and monitor a variety of disease indications
  - Urine based proof-of-principal established in HIV
    - Identified HIV-specific exosomes in 111 HIV-infected individuals, but not in the urine of 35 HIV negative control subjects.
    - A potential noninvasive global strategy to diagnose HIV infection.
    - In collaboration with Morehouse School of Medicine, who conducted the study





## Chronic Traumatic Encephalopathy (CTE)





- Discovery of CTE biomarker candidate (TauSome™)
- TauSome testing was conducted in the DETECT study
  - In collaboration with the Boston University CTE Center
    - Principal Investigator: Robert Stern Ph.D.
  - Goal: a test that could detect CTE in living individuals
  - 78 former NFL players (high risk CTE group)
  - 16 athlete controls (low risk CTE group)




***Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy***

Stern, Tripodis, Baugh, Fritts, Martin, Chaisson, Cantu, Joyce, Shah, Ikezu, Zhang, Gercel-Taylor, & Taylor

*J Alzheimer's Disease*, 2016

- Findings suggest that TauSome plasma levels may be an accurate, noninvasive CTE biomarker
  - TauSome levels significantly higher in the NFL group
  - TauSome levels correlated with cognitive decline







- TauSome Next Steps (more testing required)
  - Validate that TauSomes are brain-derived
  - Refine technique to ELLSA-antibody or other scalable methodology
  - Initiate TauSome studies in other tauopathies
  - Initiate TauSome studies in other high-risk CTE groups
  - **TauSome testing to be included in new (up to a 17-sites) CTE study funded by a \$16 million NIH grant**





# Summary

- Clinical-stage Company
- Lead therapeutic – The Aethlon Hemopurifier®
  - Broad-spectrum countermeasure against emerging pandemic threats
  - Discovered to capture cancer-promoting exosomes
    - Significant unmet need in cancer care
- Exosome Sciences, Inc. (*diagnostic subsidiary*)
  - ELLSA™ exosome isolation platform (*virus & cancer*)
  - Discovered a candidate biomarker to diagnose CTE



# IMMUNOTHERAPEUTIC TECHNOLOGIES TO COMBAT INFECTIOUS DISEASE & CANCER



SAVE LIVES





## Acknowledgement and Thanks

- Team Aethlon
- Battelle Memorial Research Institute
- Boston University CTE Center
- DaVita Med Center Dialysis
- Defense Advanced Research Projects Agency (DARPA)
- Frankfurt University Hospital
- Medanta Medicity, Fortis and Apollo Hospitals
- Morehouse School of Medicine
- National Institute of Virology (NIV) Pune, India
- Philipps University Marburg
- U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID)
- U.S. Centers for Disease Control (CDC)



## CONTACT:

### **Aethlon Medical, Inc**

9635 Granite Ridge Drive  
Suite 100  
San Diego, California 92123

Jim Joyce  
Chairman & CEO  
jj@aethlonmedical.com  
858.459.7800 x301

